Johnson & Johnson receives positive CHMP opinion for
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of...
Source: globenewswire.com
Diverse Models News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Diverse Models. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Diverse Models Today - Breaking & Trending Today
Johnson & Johnson : Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer -December 21, 2023 at 08:44 am EST
News Release Media Contacts: Zayn Qureshi +44 7760 334666 Email: zqureshi@its.jnj.com Investor...
Source: marketscreener.com
Landmark Phase 3 MARIPOSA Study Shows
Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in...
Source: globenewswire.com
Rombo Picks Review: Striking the Perfect Chord Between Quality and Innovation
Based in Stuttgart, Germany, Rombo Picks is a small, two-person business led by Carlos Diez Macia and Judith Heindorf.
Source: bassmusicianmagazine.com
New Long-Term Data from the CHRYSALIS Study Show Median
Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung cancer who have a MET positive...
Source: globenewswire.com